Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico
Brief Summary: In September 2009 the National Vaccination Council approved the policy for anti-HPV vaccination in 9-year-old girls with an extended scheme of 0, 6, and 60 months, under the following justification:

* Antibody induction due to the vaccine is greater than that produced by natural exposure to the virus
* Immune response in girls 9 to 11 years of age is similar to the response obtained after three doses in women 16 to 26 years of age
* The third dose will be administered at the time when maximum protection is required, near the onset of sexual activity Thus the National Institute of Public Health was commissioned to monitor anti-HPV antibody levels in women who received the anti-HPV vaccine to determine non-inferiority of the extended scheme in 9-year-old girls compared with the traditional scheme of 3 doses in women 18 to 24 years of age. To this end, a sentinel cohort will be formed to evaluate immunogenicity levels in 3 age groups, and stratified by vaccine type. The hypothesis is that in 9-year-old girls who are administered the amplified HPV vaccination scheme (0-6-60) show immunogenicity levels that are not lower than those of adult women who have been administered the traditional scheme (0-1/2-6).

The main objectives are to monitor the levels of immunity induced by vaccination against HPV with two vaccination schemes with the quadrivalent vaccine: Traditional Extended (0-6-60 months) and traditional (0-2-6); Monitoring levels of immunity induced by vaccination against HPV with three vaccine schemes with bivalent vaccine: Extended (0-6-60 months), traditional (0-1-6) and two doses (0- 6); as well as evaluating the interchangeability of the bivalent and quadrivalent vaccines in the third dose of extended scheme. The study design is to create a sentinel cohort of women vaccinated against HPV in the following comparison groups:

* Women of nine years with extended vaccination scheme with three doses of quadrivalent vaccine (0-6-60)
* Women of nine years with extended vaccination scheme with two doses of the quadrivalent vaccine and the third dose with bivalent (0-6-60)
* Women of nine years with traditional vaccination scheme with the quadrivalent HPV vaccine (0-2-6)
* Women between 18 and 24 years with traditional vaccination scheme with the quadrivalent HPV vaccine (0-2-6)
* Women of nine years with extended vaccination scheme with three doses of bivalent vaccine (0-6-60)
* Women of nine years with extended vaccination scheme with two doses of bivalent vaccine and the third tetravalent dose
* Women of nine years with two vaccine doses scheme with the bivalent HPV vaccine (0-6)
* Women of nine years with traditional vaccination scheme with bivalent HPV vaccine (0-1-6)
* Women between 18 and 24 years with traditional vaccination scheme with bivalent HPV vaccine (0-1-6)
* To monitoring HPV infections, at month 61 of follow-up, a group of 400 women aged 14-15 years, who have not been vaccinated against HPV, will be invited , in order to make the monitoring of occurrence of HPV infections in urine per month 61, 72, 96 and 120 post dose 0 in vaccinated groups


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: hepatitis A inactivated virus vaccine | Intervention Type: BIOLOGICAL; Name: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: hepatitis A inactivated virus vaccine; Assigned to Arm(s): Havrix Group
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 vaccine (Cervarix™) | Arm Label: Aimmugen Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Aimmugen™ | Intervention Type: BIOLOGICAL; Name: HPV-16/18 vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Aimmugen™; Assigned to Arm(s): Aimmugen Group
D: Arm Label: Tetravalent Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tetravalent Vaccine | Arm Label: Bivalent Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent Vaccines | Intervention Type: BIOLOGICAL; Name: Bivalent Vaccines; Assigned to Arm(s): Bivalent Vaccine | Intervention Type: BIOLOGICAL; Name: Tetravalent Vaccine; Assigned to Arm(s): Tetravalent Vaccine

Answer: D